MX2012007682A - Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso. - Google Patents

Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.

Info

Publication number
MX2012007682A
MX2012007682A MX2012007682A MX2012007682A MX2012007682A MX 2012007682 A MX2012007682 A MX 2012007682A MX 2012007682 A MX2012007682 A MX 2012007682A MX 2012007682 A MX2012007682 A MX 2012007682A MX 2012007682 A MX2012007682 A MX 2012007682A
Authority
MX
Mexico
Prior art keywords
fatty liver
vaccine composition
development
atherosclerosis disease
novel
Prior art date
Application number
MX2012007682A
Other languages
English (en)
Other versions
MX347400B (es
Inventor
Armando Perez Torres
Jaime Mas Oliva
Blanca Alicia Delgado Coello
Victor Guadalupe Garcia Gonzalez
Original Assignee
Univ Mexico Nacional Autonoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mexico Nacional Autonoma filed Critical Univ Mexico Nacional Autonoma
Priority to MX2012007682A priority Critical patent/MX347400B/es
Priority to PCT/MX2013/000078 priority patent/WO2014003531A1/es
Priority to ES13809203T priority patent/ES2873517T3/es
Priority to US14/411,233 priority patent/US9539312B2/en
Priority to EP13809203.6A priority patent/EP2868327B1/en
Publication of MX2012007682A publication Critical patent/MX2012007682A/es
Publication of MX347400B publication Critical patent/MX347400B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A61K47/6909—Micelles formed by phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención provee una novedosa composición vacunal de nanopartículas micelares de administración intranasal para tratar y/o prevenir la enfermedad denominada ateroesclerosis o el hígado graso no alcohólico que resulta de un metabolismo anormal de los lípidos circulantes. Lo novedoso de la composición vacunal de la presente invención es el uso de lípidos de arqueobacterias, lisofosfatidilcolina y fosfatidilcolina que permiten darle estabilidad a las nanopartículas y facilitar la presentación del antígeno en su conformación secundaria peptídica adecuada. También se presenta un novedoso proceso para la preparación de la composición vacunal que permite obtener nanopartículas micelares homogéneas y con alta estabilidad.
MX2012007682A 2012-06-28 2012-06-29 Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso. MX347400B (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MX2012007682A MX347400B (es) 2012-06-29 2012-06-29 Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
PCT/MX2013/000078 WO2014003531A1 (es) 2012-06-28 2013-06-26 Vacuna de aplicación nasal contra el desarrollo de la enfermedad aterosclerótica y el hígado graso
ES13809203T ES2873517T3 (es) 2012-06-29 2013-06-26 Vacuna nasal contra el desarrollo de la enfermedad aterosclerótica e hígado graso
US14/411,233 US9539312B2 (en) 2012-06-28 2013-06-26 Nasal vaccine against the development of atherosclerosis disease and fatty liver
EP13809203.6A EP2868327B1 (en) 2012-06-29 2013-06-26 Nasal vaccine against the development of atherosclerosis disease and fatty liver

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2012007682A MX347400B (es) 2012-06-29 2012-06-29 Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.

Publications (2)

Publication Number Publication Date
MX2012007682A true MX2012007682A (es) 2013-12-30
MX347400B MX347400B (es) 2017-04-18

Family

ID=49783566

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007682A MX347400B (es) 2012-06-28 2012-06-29 Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.

Country Status (5)

Country Link
US (1) US9539312B2 (es)
EP (1) EP2868327B1 (es)
ES (1) ES2873517T3 (es)
MX (1) MX347400B (es)
WO (1) WO2014003531A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201627318A (zh) 2014-10-22 2016-08-01 臺北醫學大學 膽固醇酯轉運蛋白抗原肽及其融合蛋白以及其組合物及應用
WO2017024312A1 (en) * 2015-08-06 2017-02-09 Autotelic Llc Phospholipid-cholesteryl ester nanoformulations and related methods
CN106729681B (zh) * 2016-12-21 2020-02-21 上海交通大学医学院附属新华医院 一种提高抗原免疫原性的纳米化载体蛋白平台

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410022B1 (en) 1995-05-01 2002-06-25 Avant Immunotherapeutics, Inc. Modulation of cholesteryl ester transfer protein (CETP) activity
EP0831881B1 (en) * 1995-06-06 2003-03-12 Avant Immunotherapeutics, Inc. Cetp for increasing hdl cholesterol level
US6132789A (en) * 1995-12-15 2000-10-17 National Research Council Of Canada Archaeosomes, archaeosomes containing coenzyme Q10, and other types of liposomes containing coenzyme Q10 as adjuvants and as delivery vehicles
US6846808B1 (en) 1996-05-01 2005-01-25 Avant Immunotherapeutics, Inc. Plasmid-based vaccine for treating atherosclerosis
JP2894445B2 (ja) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6284553B1 (en) 1999-02-16 2001-09-04 Advanced Micro Devices, Inc. Location dependent automatic defect classification
ES2292493T3 (es) * 1999-12-13 2008-03-16 Universidad Nacional Autonoma De Mexico Metodo inmunoenzimatico de cuantificacion.
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
AT500835B1 (de) 2004-09-13 2007-12-15 Affiris Forschungs & Entwicklungs Gmbh Cholinestertransport-protein-mimotop als atherosklerose-medikament
TW200833709A (en) * 2006-12-15 2008-08-16 Ca Nat Research Council Archaeal polar lipid aggregates for administration to animals

Also Published As

Publication number Publication date
WO2014003531A1 (es) 2014-01-03
ES2873517T3 (es) 2021-11-03
EP2868327A4 (en) 2015-07-22
EP2868327B1 (en) 2021-03-03
EP2868327A1 (en) 2015-05-06
MX347400B (es) 2017-04-18
US9539312B2 (en) 2017-01-10
US20150328296A1 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
MX350258B (es) Emulsiones cationicas de aceite en agua.
MX2019005287A (es) Lipidos cationicos para suministro de acido nucleico y su preparacion.
CY1124499T1 (el) Λιπιδια για συστασεις διανομης θεραπευτικου παραγοντα
MX2020011696A (es) Formulacion arn para inmunoterapia.
PL3368507T3 (pl) Nowe preparaty lipidów i nanocząstek lipidowych do dostarczania kwasów nukleinowych
MX2015012201A (es) Formulaciones modificadas de liposomas de docetaxel.
EP4438625A3 (en) Formulation for anti-alpha4beta7 antibody
MY176018A (en) Composition useful for the treatment of lipid metabolism disorders
MX343410B (es) Emulsiones cationicas de agua en aceite.
BR112015022476A2 (pt) composições de oxaliplatina de lipossoma para terapia de câncer
PH12015500221A1 (en) Oil-in-water emulsion comprising deamidated protein
BR112015022415A2 (pt) composições de cisplatina lipossômica para terapia contra câncer
MX2015007082A (es) Métodos de administración de composiciones que comprenden ácido docosapentanoico.
TN2013000373A1 (en) Pharmaceutical formulation comprising inositol
PH12018500036A1 (en) Nutritional compositions containing phosphatidylethanolamine, sphingomyelin and docosahexaenoic acid
NZ702472A (en) Oil/water-emulsion-type topical compositions containing a retinoid
AR105144A1 (es) Composiciones nutricionales y métodos para promover el desarrollo cognitivo
IN2014CN03214A (es)
WO2012014073A3 (en) Vaccines against pregnancy-associated malaria
MX364946B (es) Sistema adyuvante mejorado para la administración de vacunas orales.
WO2013007637A3 (en) Cosmetic compositions in the form of water-in-oil emulsions including a jasmonic acid derivative and a silicone surfactant
CY1123453T1 (el) Σκευασμα rna για ανοσοθεραπεια
MX347400B (es) Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
PH12014501144A1 (en) Oil-in-water cosmetic compositions
PH12016502544B1 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor

Legal Events

Date Code Title Description
FG Grant or registration